Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ:HEPA) is set to participate in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will offer a pre-recorded presentation available on-demand for registered attendees and on its website starting January 10. Hepion's lead drug candidate, CRV431, is in clinical development for treating non-alcoholic steatohepatitis (NASH), aiming to mitigate liver disease impacts. The company leverages its AI platform, AI-POWR™, to enhance patient selection and potentially expedite drug development timelines.

Positive

• Participation in H.C. Wainwright BioConnect Conference may enhance investor visibility.
• CRV431 shows promising results in reducing liver fibrosis and hepatocellular carcinoma.
• AI-POWR™ platform aims to improve patient response identification for CRV431.

Negative

• None.

EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

Hepion’s pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, January 10, 2022, the presentation will also be available on the Company's website at www.hepionpharma.com under “Events” in the “Investors” section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies.

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

FAQ

What is Hepion Pharmaceuticals' participation in the BioConnect Conference 2022?

Hepion Pharmaceuticals will participate in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022, featuring a pre-recorded presentation.

What is the lead drug candidate of Hepion Pharmaceuticals?

Hepion's lead drug candidate is CRV431, which is currently in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).

How does Hepion use AI in their drug development?

Hepion uses its proprietary AI platform, AI-POWR™, to identify which NASH patients may best respond to CRV431, aiming to shorten development timelines.

What are the potential benefits of CRV431?

CRV431 has shown potential in reducing liver fibrosis and tumor burden associated with hepatocellular carcinoma in preclinical studies.